US › Healthcare

Context Therapeutics Inc (CNTX)

US · Healthcare · Biotechnology

$0.38+1.16%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-14.6M

EPS

$-0.15

EPS estimate

$-0.10

EPS came in at -0.15 against a street estimate of -0.10 — a miss of 50.0%.

Key statistics

Market cap

$32.2M

Forward P/E

0.0

P/B

0.85

Book value

$0.41

EPS (TTM)

$-0.48

52-week high

$3.62

52-week low

$0.34

50-day MA

$0.53

200-day MA

$1.62

Beta

1.69

Analyst view

Analysts rate Context Therapeutics Inc a buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $4.25.

Shareholding

Insiders

1.57%

Institutions

69.12%

Largest institutional holders

Fund	Stake
Deep Track Capital, LP	8.08%
Nextech Invest, Ltd.	8.08%
Soleus Capital Management, L.P.	7.69%
Avidity Partners Management LP	5.44%
Franklin Templeton Inc	4.14%
Vanguard Capital Management, LLC	3.74%
Octagon Capital Advisors LP	3.32%
Marshall Wace Asset Management Ltd	3.21%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Context Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.